Mark C. Kelley

6.9k citations
56 papers · 4.8k · 2 hit papers · h-index 32

Impact in

  • Cancer Research top 1%
    • Breast Cancer Treatment Studies
  • Oncology top 1%
    • Cutaneous Melanoma Detection and Management
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research

Papers in

  • Oncology 22
    • Cutaneous Melanoma Detection and Management 9
    • Cancer-related Molecular Pathways 5
    • Cancer Immunotherapy and Biomarkers 4
  • Molecular Biology 13
    • Melanoma and MAPK Pathways 7
Co-authors
Douglas B. Johnson (10 shared papers)Nora Hansen (2 shared papers)Edwin C. Glass (3 shared papers)Ingrid M. Meszoely (17 shared papers)Ingrid A. Mayer (13 shared papers)Jeffrey A. Sosman (10 shared papers)Wei Ye (1 shared paper)Armando E. Giuliano (1 shared paper)
Journals
Clinical Cancer Research (6 papers)Journal of Clinical Oncology (4 papers)Annals of Surgical Oncology (4 papers)Magnetic Resonance in Medicine (2 papers)The American Journal of Surgery (2 papers)
Partner nations
United StatesAustraliaCanada

In The Last Decade

Mark C. Kelley

55 papers receiving 4.7k citations

Mark C. Kelley's Hit Papers

Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy 2019 · 559 citations
5590+4+8Years since publication200400600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

  • it has ≥500 total citations;
  • it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
  • it reaches the top citation threshold in at least one of its specific research topics.
  1. 2019 Nature Nanotechnology
  2. 2013 Cancer Discovery

Peers

Mark C. Kelley
Comparison fields: 5 of 117
  • Cancer Research 966
  • Oncology 1.6k
  • Biophysics 296
  • Radiology, Nuclear Medicine and Imaging 837
  • Immunology 792
Replace Brian J. Czerniecki with:
Brian J. Czerniecki United States
Andrew M. Hanby United Kingdom
Gerald E. Marti United States
Alessandro Testori Italy
Kenneth P. Olive United States
Françoise Rothé Belgium
Maarit Bärlund Finland
Brian B. Haab United States
Niels Halama Germany
Wilma E. Mesker Netherlands
Mark C. Kelley relative to Brian J. Czerniecki United States Brian J. Czerniecki's profile →
Citations per field
00.5×1.5×
Brian J. Czerniecki · 1×
Citations per year

Countries citing papers authored by Mark C. Kelley

Since Specialization
Citations

This map shows the geographic impact of Mark C. Kelley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Kelley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Kelley more than expected).

Fields of papers citing papers by Mark C. Kelley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark C. Kelley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Kelley. The network helps show where Mark C. Kelley may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark C. Kelley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark C. Kelley Line = papers co-authored together Mark C. Kelley links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 56 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Cancer Discovery ·Hubing Shi, Willy Hugo, Xiangju Kong, Aayoung Hong, Richard C. Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B. Johnson, Kimberly B. Dahlman, Mark C. Kelley, Richard Kefford, Bartosz Chmielowski, John A. Glaspy, Jeffrey A. Sosman, Nicolas van Baren, Georgina V. Long, Antoni Ribas, Roger S. Lo
Hit paper breakdown →		2013718
2
Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy
Nature Nanotechnology ·Daniel Shae, Kyle W. Becker, Plamen P. Christov, Dong Soo Yun, Abigail K. R. Lytton‐Jean, Sema Sevimli, Manuel Ascano, Mark C. Kelley, Douglas B. Johnson, Justin M. Balko, John T. Wilson
Hit paper breakdown →		2019559
3
Prospective Observational Study of Sentinel Lymphadenectomy Without Further Axillary Dissection in Patients With Sentinel Node–Negative Breast Cancer
Journal of Clinical Oncology ·Armando E. Giuliano, Philip I. Haigh, Meghan B. Brennan, Nora Hansen, Mark C. Kelley, Wei Ye, Edwin C. Glass, Roderick R. Turner
2000469
4
Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results
Magnetic Resonance Imaging ·Thomas E. Yankeelov, Martin Lepage, Anuradha Chakravarthy, Elizabeth E. Broome, Kenneth J. Niermann, Mark C. Kelley, Ingrid M. Meszoely, Ingrid A. Mayer, Cheryl R. Herman, Kevin McManus, Ronald R. Price, John C. Gore
2006265
5
Development of a spatially offset Raman spectroscopy probe for breast tumor surgical margin evaluation
Journal of Biomedical Optics ·Matthew D. Keller, Elizabeth Vargis, Nara de Matos Granja, Robert H. Wilson, Mary‐Ann Mycek, Mark C. Kelley, Anita Mahadevan‐Jansen
2011160
6
Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma
Immunotherapy ·Douglas B. Johnson, Igor Puzanov, Mark C. Kelley
2015151
7
Efficacy of Lymphatic Mapping, Sentinel Lymphadenectomy, and Selective Complete Lymph Node Dissection as a Therapeutic Procedure for Early-Stage Melanoma
Annals of Surgical Oncology ·Richard Essner, Arnold Conforti, Mark C. Kelley, Leslie A. Wanek, Stacey L. Stern, Edwin C. Glass, Donald L. Morton
1999146
8
Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation
Clinical Cancer Research ·Joshua A. Bauer, A. Bapsi Chakravarthy, Jennifer M. Rosenbluth, Deming Mi, Erin H. Seeley, Nara De Matos Granja-Ingram, Maria G. Olivares, Mark C. Kelley, Ingrid A. Mayer, Ingrid M. Meszoely, Julie A. Means‐Powell, Kimberly N. Johnson, C. Jillian Tsai, Gregory D. Ayers, Melinda E. Sanders, Robert J. Schneider, Silvia C. Formenti, Richard M. Caprioli, Jennifer A. Pietenpol
2010143
9
Multiparametric Magnetic Resonance Imaging for Predicting Pathological Response After the First Cycle of Neoadjuvant Chemotherapy in Breast Cancer
Investigative Radiology ·Xia Li, Richard G. Abramson, Lori R. Arlinghaus, Hakmook Kang, Anuradha Chakravarthy, Vandana G. Abramson, Jaime Farley, Ingrid A. Mayer, Mark C. Kelley, Ingrid M. Meszoely, Julie Means‐Powell, Ana M. Grau, Melinda E. Sanders, Thomas E. Yankeelov
2014130
10
Accuracy of Intraoperative Gross Examination of Surgical Margin Status in Women Undergoing Partial Mastectomy for Breast Malignancy
The American Surgeon ·Glen C. Balch, Suhail K. Mithani, Jean F. Simpson, Mark C. Kelley
2005112
11
Intraoperative lymphatic mapping for early-stage melanoma of the head and neck
The American Journal of Surgery ·Peter J. Bostick, Richard Essner, Terry Sarantou, Mark C. Kelley, Edwin C. Glass, Leland J. Foshag, Stacey L. Stern, Donald L. Morton
1997111
12
Lymphatic mapping and sentinel lymphadenectomy for breast cancer
The American Journal of Surgery ·Mark C. Kelley, Nora Hansen, K. M. McMasters
2004110
13
DCE‐MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: Pilot study findings
Magnetic Resonance in Medicine ·Xia Li, Lori R. Arlinghaus, Gregory D. Ayers, A. Bapsi Chakravarthy, Richard G. Abramson, Vandana G. Abramson, Nkiruka C. Atuegwu, Jaime Farley, Ingrid A. Mayer, Mark C. Kelley, Ingrid M. Meszoely, Julie Means‐Powell, Ana M. Grau, Melinda E. Sanders, Sandeep R. Bhave, Thomas E. Yankeelov
201397
14
Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment
Frontiers in Oncology ·Joe T. Sharick, Christine M. Walsh, Carley M. Sprackling, Cheri A. Pasch, Dan L. Pham, Karla Esbona, Alka Choudhary, Rebeca García‐Varela, Mark E. Burkard, Stephanie M. McGregor, Kristina A. Matkowskyj, Alexander A. Parikh, Ingrid M. Meszoely, Mark C. Kelley, Susan Tsai, Dustin A. Deming, Melissa C. Skala
202097
15
Autofluorescence and diffuse reflectance spectroscopy and spectral imaging for breast surgical margin analysis
Lasers in Surgery and Medicine ·Matthew D. Keller, Shovan Kumar Majumder, Mark C. Kelley, Ingrid M. Meszoely, Fouad Boulos, Graciela M. Olivares, Anita Mahadevan‐Jansen
201093
16
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
Clinical Cancer Research ·Jiqing Sai, Philip Owens, Sergey V. Novitskiy, Oriana E. Hawkins, Anna E. Vilgelm, Jinming Yang, Tammy Sobolik, Nicole Lavender, Andrew C. Johnson, Colt M. McClain, Gregory D. Ayers, Mark C. Kelley, Melinda E. Sanders, Ingrid A. Mayer, Harold L. Moses, Mark Boothby, Ann Richmond
201692
17
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
Science Translational Medicine ·Anna E. Vilgelm, Nabil Saleh, Rebecca L. Shattuck-Brandt, Kelsie Riemenschneider, Lauren Slesur, Sheau‐Chiann Chen, Christopher Andrew Johnson, Jinming Yang, Ashlyn Blevins, Chi Yan, Douglas B. Johnson, Rami N. Al‐Rohil, Ensar Halilovic, Rondi M. Kauffmann, Mark C. Kelley, Gregory D. Ayers, Ann Richmond
201991
18
Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast Cancers
Journal of Clinical Oncology ·Marta Guix, Nara de Matos Granja, Ingrid M. Meszoely, Theresa B. Adkins, Bobbye M. Wieman, Kerek E. Frierson, (unknown), Melinda E. Sanders, Ana M. Grau, Ingrid A. Mayer, Gary A. Pestano, Yu Shyr, Senthil K. Muthuswamy, Benjamin F. Calvo, Helen Krontiras, Ian E. Krop, Mark C. Kelley, Carlos L. Arteaga
200887
19
Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells
Cancer Research ·Anna E. Vilgelm, Jeff S. Pawlikowski, Yan Liu, Oriana E. Hawkins, Tyler A. Davis, Jessica Smith, Kevin P. Weller, Linda W. Horton, Colt M. McClain, Gregory D. Ayers, David C. Turner, David C. Essaka, Clinton F. Stewart, Jeffrey A. Sosman, Mark C. Kelley, Jeffrey Ecsedy, Jeffrey N. Johnston, Ann Richmond
201482
20
Targeting aurora kinases limits tumour growth through DNA damage‐mediated senescence and blockade of NF‐κB impairs this drug‐induced senescence
EMBO Molecular Medicine ·Yan Liu, Oriana E. Hawkins, Yingjun Su, Anna E. Vilgelm, Tammy Sobolik, Yee Mon Thu, Sara Kantrow, Ryan Splittgerber, Sarah P. Short, Katayoun I. Amiri, Jeffery A. Ecsedy, Jeffery A. Sosman, Mark C. Kelley, Ann Richmond
201281

About Mark C. Kelley

Mark C. Kelley is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Cancer Research and Surgery, having authored 56 papers that have together received 4.8k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (10 papers), MRI in cancer diagnosis (9 papers), Cutaneous Melanoma Detection and Management (9 papers), Melanoma and MAPK Pathways (7 papers), Cancer-related Molecular Pathways (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Optical Imaging and Spectroscopy Techniques (3 papers) and Spectroscopy and Chemometric Analyses (3 papers). The work is most often cited by research in Cancer Research (966 citations), Oncology (1.6k citations), Biophysics (296 citations), Radiology, Nuclear Medicine and Imaging (837 citations) and Immunology (792 citations). Mark C. Kelley has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Douglas B. Johnson, Nora Hansen, Edwin C. Glass, Ingrid M. Meszoely, Ingrid A. Mayer, Jeffrey A. Sosman, Wei Ye, Armando E. Giuliano, Meghan B. Brennan and Philip I. Haigh. Their work appears in journals such as Clinical Cancer Research, Journal of Clinical Oncology, Annals of Surgical Oncology, Magnetic Resonance in Medicine and The American Journal of Surgery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian J. CzernieckiBreakdown of academic impact, for papers by Andrew M. HanbyBreakdown of academic impact, for papers by Gerald E. MartiBreakdown of academic impact, for papers by Alessandro TestoriBreakdown of academic impact, for papers by Kenneth P. OliveBreakdown of academic impact, for papers by Françoise RothéBreakdown of academic impact, for papers by Maarit BärlundBreakdown of academic impact, for papers by Brian B. HaabBreakdown of academic impact, for papers by Niels HalamaBreakdown of academic impact, for papers by Wilma E. Mesker